

Program outline for Melanoma Congress

Program – November 1–4, 2007

Organizers – Marianne Berwick, Paul Chapmann, Rene Gonzalez, Ze'ev Ronai

Supported by:

Platinum:

**Bristol-Myers
Onyx
Pfizer
Schering-Plough**

Gold:

AstraZeneca

Silver:

**Progen
Synta**

Bronze:

**Wyeth
Vical
Hoffman-LaRoche**

***Melanoma Research Foundation
Foundation for Melanoma Research***

General Information:

Invited speakers plenary presentations – 25 min + 5 min discussion

Select abstracts plenary presentation – 15 min + 5 min discussion

Minisymposia presentations – 10 min + 5 min discussion

SMR is pleased to announce the selection of 9 poster presenters for Travel Awards. The recipients of the Travel Award were selected based on applicants abstracts that were reviewed and ranked by the steering committee for the 4th International Melanoma Congress. These awards, which are provided by the Melanoma Research Foundation (MRF) will be given during the meeting to: Olivier Bailet, S. Byron, John D'Orazio, Thomas Guadagno, Tobias Hohenauer, Mei-Yu Hsu, James Lister, Feng Liu, Stephanie Arndt.

At the 4th International Melanoma Congress, Wiley-Blackwell offers an award for the best poster. A judging committee consisting of the Editor-in-Chief and members of the Melanoma Section of *Pigment Cell & Melanoma Research* (formerly known as *Pigment Cell Research*) evaluates each poster and selects a winner based on the quality of the work. The winner of the award receives a certificate, a cash award of \$500, and a copy of Ortonne et al.: *The Pigmentary System*. The winner will be announced at the SMR dinner during the conference.

Programme

November 1, 2007

5:00 PM – Registration

7:00 PM – KEYNOTE ADDRESS GRAND BALLROOM

Boris Bastian
University of California at San Francisco
Integrating Genotypes and Phenotypes of Melanocytic Neoplasia

RECEPTION – FINANCIAL BALLROOM FOYER

Poster Session A 8:00–10:00 PM – FINANCIAL BALLROOM

Poster Session A – includes sessions E, T, M, R (#1–77)

November 2, 2007

**8:30–10:30 – Session 1 – early stages in melanoma development (why melanocytes develop into melanoma)
GRAND BALLROOM**

Chair: Dorothy Bennett	<i>How melanocytes develop into melanoma: An update</i>
Shin-Ichi Nishikawa	<i>In vitro induction of melanocyte stem cells</i>
Gavin P. Robertson	<i>Loss of Kruppel-like factor 6 promotes early melanoma development in the collagen rich environment of the skinhead</i>
Scott Lowe	<i>Dissecting Tumor Suppressor Gene Networks In Vivo</i>

**11:00–1:00 – Session 2 – late stages in melanoma development (why are melanomas so metastatic?)
GRAND BALLROOM**

Chair: Menashe Bar-Eli	<i>Regulation of melanoma metastasis by the tumor microenvironment: The role of PAF and PAFR</i>
William Harbour	<i>Integrative genomic analysis of metastasis in ocular melanoma</i>
Michael Detmar	<i>Tumor lymphangiogenesis: Impact on melanoma metastasis</i>
Joan Massague	<i>Metastasis Genes and Functions</i>

1:15–2:00 PCmR EDITORIAL BOARD MEETING

Poster Session B 2–4 PM – FINANCIAL BALLROOM

Poster Session B – includes sessions B, P (#78–160)

4:30–6:30PM – Session 3 – why melanomas don't die GRAND BALLROOM

Chair: Estela Medrano	<i>Histone deacetylase 1 is required for chromatin remodeling and maintenance of the senescent growth arrest of human melanocytic nevi</i>
David Fisher	<i>MITF and Transcriptional Regulation in Melanocyte and Melanoma</i>
Amato Giaccia	<i>Lysyl Oxidase, Hypoxia and the Pre-Metastatic Niche</i>

Speakers selected from abstracts

Pablo Lopez-Bergami	<i>Re-wired ERK-JNK signaling pathways in melanoma</i>
Barbara Bedogni	<i>Role of Notch1 in melanomagenesis</i>

FREE EVENING (MRF Scientific Advisory Committee Meeting)

November 3, 2007

8:30–10:30 – Session 1 – (what went wrong in) wiring of melanoma (I) – receptors GRAND BALLROOM

Chair: Meenhard Herlyn *Melanocyte and Melanoma Stem Cells*
 Mary J.C. Hendrix *Convergence of embryonic and tumorigenic signaling pathways resulting in melanoma tumor cell plasticity*

Marisol Soengas *Autophagy as a new rheostat of melanoma cell survival*
 Elena B. Pasquale *Eph receptors and ephrins as novel targets in melanoma*

11:00 – 1:00 Session 2 – wiring in melanoma (II) kinases GRAND BALLROOM

Chair: Martin McMahon *A new mouse model of BRAF^{V600E}-induced metastatic melanoma*
 Marcus Bosenberg *Novel Conditional Inducible Mouse Models of Melanocytic Neoplasia: Progression from Nevi to Metastatic Melanoma*

Richard Marais *Mechanisms of BRAF Signaling in Melanoma*
 Frank McCormick *The Success and Failure of Targeted Therapies*

1:30–2:15 PM – SMR BUSINESS MEETING – LUNCH – GRAND BALLROOM
UPDATES: Meenhard Herlyn, Marianne Berwick, David Fisher and Suresh Mohla

2:30 – 4:00 Minisimposia (10 Minute talks + 5 minutes discussion)

Session A – Immunobiology – GRAND SALON 3

Chair: Soldano Ferrone *Inhibition of melanoma metastasis by mAb to HMW-MAA*
 Jedd Wolchok *Immune Modulation Therapy for Melanoma*
 Raphael Clynes *Antibody therapy in cancer; immunobiological role of Fc receptors*
 Cassian Yee *Adoptive T Cell Therapy of Melanoma: Intrinsic and Extrinsic Strategies to Improve Efficacy*

Speaker selected from abstracts:

K. Dadachova *Pre-clinical development of a melanin-binding IgM antibody labeled with 188RE for Phase I clinical trial in patients with metastatic melanoma*

Session B – Gene Expression/micro RNA – FINANCIAL BALLROOM 1

Chair: Dr. Jeffrey Trent
 Kevin Brown *Genomic Analysis to Identify Mediators of Temozolomide Sensitivity in Metastatic Melanoma*

Aleksandar Sekulic, *Integrated Genomic Analysis of Malignant Melanoma Using Gene Expression Profiling and Gene Copy Number Alterations*

Nicolas Hayward *Integrative functional genomics of melanoma: correlating mRNA and miRNA expression with DNA copy number*

Alain Spatz *High Throughput Expression Studies in Primary Cutaneous Melanoma*

Speaker selected from abstracts:

Daniel Peeper *Integrative genomics to identify melanoma suppressors: C/EBP beta-IL6 axis as a critical mediator of BRAF E600-induced senescence*

Session C – Epidemiology and Prevention of Melanoma – FINANCIAL BALLROOM 2

Chair: Richard Gallagher *Sunbeds in melanoma development*
 David C. Whiteman *Exploring the causal heterogeneity of cutaneous melanomas*
 Frank L. Meyskens *Redox-active methals: the epigenetic pathogenesis of cutaneous melanoma and the role of epidemiologic and experimental evidence*

Mark Elwood *Melanoma occurrence, diagnosis and impact in Queensland, Australia*
 Marianne Berwick *Gene-environment interaction in melanoma etiology*

Programme

Session D – Clinical updates FINANCIAL BALLROOM 3

Chair: Lynn Schuchter	<i>2010: A Target Date for Improving Survival of Patients with Metastatic Melanoma</i>
Keith Flaherty	<i>Clinical Development of RAF and MEK Inhibitors</i>
Barry Allen	<i>Tumour Anti-Vascular Alpha Therapy for the Regression of Metastatic Melanoma</i>
Rhoda Alani	<i>Novel Therapies Targeting Melanoma Metastasis</i>
Kowichi Jimbow	<i>Exploitation of melanogenesis for tyrosinase-targeted DDS and chemo-thermo-immunotherapy with NPrCAP-magnetite for melanoma patients; Rationale and preliminary clinical evaluation</i>
Paul Chapman	<i>Neoadjuvant therapy with temozolomide in melanoma patients</i>

4:30–6:30 – Session 3 – (wiring in melanoma (III) transcription factors GRAND BALLROOM

Chair: Colin Goding	<i>Transcription regulation in melanoma: The Mitf code and melanoma metastasis</i>
Lionell Larue	<i>Brn2 in melanocytes</i>
Gerard Evan	<i>The therapeutic potential of targeting Myc and p53 transcription factors in cancers.</i>

Speaker selected from abstract:

Gianluca Civenni *Identification of cancer stem cells in human melanoma*

Speaker selected from abstract:

Therese Becker *The tumor suppressor Ink4a interacts with the chromatin remodeling factor BRG1 to regulate the cell cycle.*

8–10PM – SMR DINNER GRAND BALLROOM

November 4, 2007

8:30–10:30 – Session 1 – where are we headed (I) promising models and pathways – GRAND BALLROOM

Chair: Lynda Chin	<i>Genomics and Genetics of Melanoma</i>
Glenn Merlino	<i>Shedding light on the dim beginnings of melanoma</i>
Murray Robinson	<i>Population Based Drug Response Studies in Engineered Tumor Models</i>
Lewis Cantley	<i>PI3K Signaling in Cancer</i>

11:00–1:30 – Session 2 – where are we headed (II) – evolving therapies GRAND BALLROOM

Chair–Frank Haluska	<i>Evolving Approaches to Targeted Therapy for Melanoma: Basic, Preclinical and Clinical Novel Approaches</i>
Joyce James	<i>Modulating the MAPK pathway in melanoma by targeting mutated B-Raf^{V600E}</i>
Daniel Flynn	<i>Inhibitors targeting the conformational switching pocket of V600E oncogenic B-Raf kinase: Preclinical evaluation of DP-2514 and related analogs</i>
Eric W. Jacobson	<i>STA-4783: A Novel Oxidative Stress Inducer for the Treatment of Metastatic Melanoma</i>
Dana T. Aftab	<i>Targeting KIT with XL820 for the potential treatment of melanoma</i>